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Abstract
Overactive bladder (OAB) is common and is estimated to affect 16.5% 
of the adult population. In patients refractory to pharmacotherapy, new 
treatment modalities, such as neuromodulation and botulinum toxin 
(BoNT), have had encouraging results. Neuromodulation has promising 
efficacious results in treating refractory OAB, urinary retention and bowel 
dysfunction, but the reoperation rate is relatively high, and the full mech-
anism of action of sacral nerve modulation is incompletely understood. 
BoNT is another potential alternative to surgical intervention for patients 
with refractory OAB, neurogenic detrusor overactivity and interstitial cys-
titis. BoNT-A injection in patients with idiopathic detrusor overactivity 
have reported increases in cystometric capacity, improved subjective symp-
toms and urodynamic parameters, and improved quality of life. BoNT 
injection offers an efficacious, minimally invasive alternative to sacral 
nerve modulation for the treatment of refractory OAB. [Tzu Chi Med J
2008;20(2):109–111]
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1. Introduction
The overactive bladder (OAB) syndrome is characterized 
by urgency with or without urge urinary incontinence 
(UUI), and is usually associated with frequency and 
nocturia. OAB is common and is estimated to affect 
16.5% of the adult population [1]. First-line therapy 
for OAB is conservative in nature, and can include 
behavioral techniques (bladder training), physical 
therapies (electrical stimulation), and pharmacother-
apy (antimuscarinic and anticholinergic drugs). In pa-
tients refractory to pharmacotherapy, new treatment 
modalities, such as neuromodulation and botulinum 
toxin, have had encouraging results as alternatives 
to surgical intervention (augmentation and urinary 
diversion).
2. Sacral nerve modulation
Sacral nerve modulation (SNM) has been under in-
vestigation since the early 1980s. The use of SNM is 
based on the premise that electrical stimulation of 
the pudendal nerves can modulate neural reflexes 
that influence bladder and pelvic floor behavior. The 
current approved indications for SNM include refractory 
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OAB (US and Europe), urinary retention, and bowel 
dysfunction (Europe). For patients with OAB, the device 
is tested using an external stimulator for a trial period 
of days to weeks. The external stimulator is consid-
ered to be successful when the main incontinence 
symptoms improve by at least 50%; if this device is 
successful, a permanent stimulator is implanted, which 
can later be removed if necessary.
3. Clinical results with SNM
A systematic review, which included data from patients 
with 1827 implants, reported a > 50% improvement 
in UUI in 80% and 67% of patients who were included 
in randomized controlled trials and case series, re-
spectively [2]. Incontinence episodes, leakage severity, 
voiding frequency, and pad use were significantly lower 
after implantation, and benefits were reported to per-
sist for up to 3–5 years. Adverse effects, primarily pain 
at the lead or implant site, new pain such as leg pain 
and infection, were documented in 27 studies, with an 
overall reoperation rate of 33%. Despite the promising 
efficacious results with this technique, the reoperation 
rate is relatively high, and the full mechanism of action 
of SNM is incompletely understood.
4. Botulinum neurotoxin
Botulinum neurotoxin (BoNT) is another potential 
alternative to surgical intervention for patients with 
refractory OAB. BoNT is believed to bind at periph-
eral cholinergic terminals, inhibiting the exocytosis 
of synaptic vesicles containing acetylcholine at the 
neuromuscular junction, which results in regional de-
creased contractility at the site of injection. A dual 
mechanism of action of BoNT has been proposed: in 
addition to binding to cholinergic terminals, BoNT might 
also affect afferent nervous transmission, thereby 
decreasing urgency [3]. Apostolidis et al [4] proposed 
that the primary afferent effect of BoNT involves the 
inhibition of acetylcholine, ATP, and substance P, and 
a reduction in the axonal expression of the capsaicin 
and purinergic (P2X) receptors. These investigators 
further speculate that this action might be followed by 
central desensitization through a decrease in uptake 
of substance P and neurotrophic factors. Seven BoNT 
serotypes have been isolated, two of which—BoNT-A 
and BoNT-B—have been investigated in treating bladder 
dysfunction. Although BoNT has not been approved by 
the FDA for urologic use in the US, it has been approved 
for other indications for > 25 years, and BoNT is 
currently being investigated for urologic indications 
in phase III trials worldwide. Currently, BoNT is avail-
able as three major commercial preparations: 
BOTOX® (BoNT-A; Allergan, Irvine, CA, USA), Dysport®
(BoNT-A; Ipsen, Slough, UK) and Myobloc® (BoNT-B; 
Solstice Neurosciences, San Diego, CA, USA). Each 
of these preparations has different dosages, safety 
profiles, and efficacy profiles, and they cannot be 
used interchangeably.
5. Clinical results with BoNT
In a double-blind, placebo-controlled trial of bladder 
injection of 200 or 300 units of BoNT-A, for the treat-
ment of neurogenic detrusor overactivity (DO), Schurch 
et al [5] reported a significant reduction in UUI epi-
sodes, an increase in cystometric capacity, improved 
quality of life, and no systemic side effects at 24 weeks. 
Double-blind, placebo-controlled [6] and open-label 
[7] trials of BoNT-A injection in patients with idio-
pathic DO have reported increases in cystometric 
capacity, improved subjective symptoms and urody-
namic parameters, and improved quality of life. Although 
the long-term effects of neurotoxin instillation in the 
bladder are unknown, to date, no systemic effects from 
BoNT bladder injection have been reported. Localized 
side effects in these trials have included urinary tract 
infection (22%) [5] and increased post-void residual 
volume requiring clean intermittent catheterization 
(38%) [6]. In a double-blind, placebo-controlled trial 
of BoNT-B injections in patients with refractory DO, 
Ghei et al [8] reported symptomatic and quality-of-life 
improvement with a 6-week duration of action, and 
they concluded that the benefits of BoNT-B might 
not be long-lasting enough to justify its use over 
BoNT-A.
BoNT-A chemical denervation is reversible, and 
therefore the main disadvantage of BoNT-A injection 
is the need to undergo repeated injections. The efficacy 
of repeat BoNT-A injections is, however, maintained: 
in our series, every patient who responded well to 
the initial BoNT-A injection had similar clinical im-
provement after subsequent (up to six) injections 
[9]. Although the durability of SNM is longer than that 
of BoNT-A (3–5 years for SNM [2] versus 6–9 months 
for BoNT-A injection [9]), the revision rate for SNM 
is > 30%, and two surgical procedures are required 
for initial device implantation. BoNT injection under 
local anesthesia is an attractive alternative to SNM 
because it is less time-consuming and requires no 
adjustments/programming. While the risk of urinary 
retention is a concern in patients receiving BoNT, it 
has been observed in < 10% of our closely followed-up 
patients [9].
In our practice, we inject between 10 and 30 loca-
tions (100–300 units of BoNT-A diluted in 10–30 mL 
sterile saline), targeting the bladder base and trigone 
areas [9]. The dosage and number of injections should 
be tailored to the individual needs of each patient. Many 
patients with neurogenic DO are already performing 
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clean intermittent catheterization at the time of eval-
uation, and our goal in these patients is to completely 
paralyze the bladder, to maximize symptomatic re-
lief and to reduce detrusor pressure. In patients with 
OAB or interstitial cystitis, our goal is to provide symp-
tomatic relief, while avoiding negative side effects 
such as straining to void and urinary retention. Our 
modified injection technique to target sensory nerve 
pathways and to limit toxin dosage and distribution 
in patients with idiopathic DO has previously been 
described [10].
While BoNT injection appears to be expensive, 
Kalsi et al [11] reported in their cost analysis that 
BoNT therapy for neurogenic or idiopathic DO costs 
UK£826 per patient, with a cost-effectiveness ratio 
of UK£617 per patient-year with ≥ 25% clinical im-
provement. Direct costs (excluding physician and 
hospital charges) in Pittsburgh are US$1280 per 
BoNT injection compared with US$18,125 for SNM 
implantation. Further cost comparison with alterna-
tive therapies is warranted.
6. Conclusion
BoNT injection offers an efficacious, minimally invasive 
alternative to SNM for the treatment of refractory 
OAB. Currently available data do not show superiority 
for one treatment plan, and therapy options in these 
patients should be tailored to specific patient and 
physician preference.
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